Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

35,563 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Selective Akt inhibitors synergize with tyrosine kinase inhibitors and effectively override stroma-associated cytoprotection of mutant FLT3-positive AML cells.
Weisberg E, Liu Q, Zhang X, Nelson E, Sattler M, Liu F, Nicolais M, Zhang J, Mitsiades C, Smith RW, Stone R, Galinsky I, Nonami A, Griffin JD, Gray N. Weisberg E, et al. Among authors: liu q, liu f. PLoS One. 2013;8(2):e56473. doi: 10.1371/journal.pone.0056473. Epub 2013 Feb 21. PLoS One. 2013. PMID: 23437141 Free PMC article.
Discovery of a selective irreversible BMX inhibitor for prostate cancer.
Liu F, Zhang X, Weisberg E, Chen S, Hur W, Wu H, Zhao Z, Wang W, Mao M, Cai C, Simon NI, Sanda T, Wang J, Look AT, Griffin JD, Balk SP, Liu Q, Gray NS. Liu F, et al. Among authors: liu q. ACS Chem Biol. 2013 Jul 19;8(7):1423-8. doi: 10.1021/cb4000629. Epub 2013 Apr 26. ACS Chem Biol. 2013. PMID: 23594111
Discovery of a potent and selective DDR1 receptor tyrosine kinase inhibitor.
Kim HG, Tan L, Weisberg EL, Liu F, Canning P, Choi HG, Ezell SA, Wu H, Zhao Z, Wang J, Mandinova A, Griffin JD, Bullock AN, Liu Q, Lee SW, Gray NS. Kim HG, et al. Among authors: liu q, liu f. ACS Chem Biol. 2013 Oct 18;8(10):2145-50. doi: 10.1021/cb400430t. Epub 2013 Aug 13. ACS Chem Biol. 2013. PMID: 23899692 Free PMC article.
Discovery of a potent, covalent BTK inhibitor for B-cell lymphoma.
Wu H, Wang W, Liu F, Weisberg EL, Tian B, Chen Y, Li B, Wang A, Wang B, Zhao Z, McMillin DW, Hu C, Li H, Wang J, Liang Y, Buhrlage SJ, Liang J, Liu J, Yang G, Brown JR, Treon SP, Mitsiades CS, Griffin JD, Liu Q, Gray NS. Wu H, et al. Among authors: liu j, liu q, liu f. ACS Chem Biol. 2014 May 16;9(5):1086-91. doi: 10.1021/cb4008524. Epub 2014 Mar 17. ACS Chem Biol. 2014. PMID: 24556163 Free PMC article.
Upregulation of IGF1R by mutant RAS in leukemia and potentiation of RAS signaling inhibitors by small-molecule inhibition of IGF1R.
Weisberg E, Nonami A, Chen Z, Nelson E, Chen Y, Liu F, Cho H, Zhang J, Sattler M, Mitsiades C, Wong KK, Liu Q, Gray NS, Griffin JD. Weisberg E, et al. Among authors: liu q, liu f. Clin Cancer Res. 2014 Nov 1;20(21):5483-95. doi: 10.1158/1078-0432.CCR-14-0902. Epub 2014 Sep 3. Clin Cancer Res. 2014. PMID: 25186968 Free PMC article.
Dual inhibition of AKT/FLT3-ITD by A674563 overcomes FLT3 ligand-induced drug resistance in FLT3-ITD positive AML.
Wang A, Wu H, Chen C, Hu C, Qi Z, Wang W, Yu K, Liu X, Zou F, Zhao Z, Wu J, Liu J, Liu F, Wang L, Stone RM, Galinksy IA, Griffin JD, Zhang S, Weisberg EL, Liu J, Liu Q. Wang A, et al. Among authors: liu j, liu x, liu q, liu f. Oncotarget. 2016 May 17;7(20):29131-42. doi: 10.18632/oncotarget.8675. Oncotarget. 2016. PMID: 27074558 Free PMC article.
Discovery of N-(3-((1-Isonicotinoylpiperidin-4-yl)oxy)-4-methylphenyl)-3-(trifluoromethyl)benzamide (CHMFL-KIT-110) as a Selective, Potent, and Orally Available Type II c-KIT Kinase Inhibitor for Gastrointestinal Stromal Tumors (GISTs).
Wang Q, Liu F, Wang B, Zou F, Chen C, Liu X, Wang A, Qi S, Wang W, Qi Z, Zhao Z, Hu Z, Wang W, Wang L, Zhang S, Wang Y, Liu J, Liu Q. Wang Q, et al. Among authors: liu j, liu x, liu q, liu f. J Med Chem. 2016 Apr 28;59(8):3964-79. doi: 10.1021/acs.jmedchem.6b00200. Epub 2016 Apr 14. J Med Chem. 2016. PMID: 27077705
Characterization of selective and potent PI3Kδ inhibitor (PI3KDIN- 015) for B-Cell malignances.
Liu X, Wang A, Liang X, Chen C, Liu J, Zhao Z, Wu H, Deng Y, Wang L, Wang B, Wu J, Liu F, Fernandes SM, Adamia S, Stone RM, Galinsky IA, Brown JR, Griffin JD, Zhang S, Loh T, Zhang X, Wang W, Weisberg EL, Liu J, Liu Q. Liu X, et al. Among authors: liu j, liu q, liu f. Oncotarget. 2016 May 31;7(22):32641-51. doi: 10.18632/oncotarget.8702. Oncotarget. 2016. PMID: 27081697 Free PMC article.
35,563 results
You have reached the last available page of results. Please see the User Guide for more information.